Advertisement

Loading...

Innovent Biologics, Inc.

1801.HKHKSE
Healthcare
Biotechnology
HK$90.50
HK$5.60(6.60%)
Hong Kong Market is Open • 10:08

Innovent Biologics, Inc. (1801.HK) Stock Competitors & Peer Comparison

See (1801.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1801.HKHK$90.60+5.23%146.1B160.19HK$0.53N/A
6160.HKHK$184.60+7.89%257.8B115.17HK$1.49N/A
2269.HKHK$34.98+11.54%136.5B25.21HK$1.31N/A
9926.HKHK$139.00+4.43%119.8B-119.45-HK$1.09N/A
1177.HKHK$6.33+8.21%105.3B39.27HK$0.15+1.53%
1530.HKHK$25.18+3.71%53.4B20.77HK$1.09+1.10%
9995.HKHK$109.30+10.57%52.7B65.62HK$1.46N/A
3759.HKHK$20.74+13.52%51.4B19.40HK$0.97+1.16%
2696.HKHK$75.25+8.04%37.9B40.79HK$1.71N/A
6821.HKHK$103.00+28.51%33.3B28.09HK$3.24+1.32%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1801.HK vs 6160.HK Comparison April 2026

1801.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1801.HK stands at 146.1B. In comparison, 6160.HK has a market cap of 257.8B. Regarding current trading prices, 1801.HK is priced at HK$90.60, while 6160.HK trades at HK$184.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1801.HK currently has a P/E ratio of 160.19, whereas 6160.HK's P/E ratio is 115.17. In terms of profitability, 1801.HK's ROE is +0.05%, compared to 6160.HK's ROE of +0.07%. Regarding short-term risk, 1801.HK is more volatile compared to 6160.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1801.HK.Check 6160.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions